IGC Pharma, Inc. IGC
Set alert
0.19 USD -0.01 -7.13%
At close
0.19 +0.01 +4.86%
Pre-market · Nov 2, 8:32 AM ET
0.1808 Day range 0.197
0.08 52-week range 0.45
- YTD
- -33.93%
- 1 year
- -53.75%
- Open
- 0.191
- Prev close
- 0.1992
- Mkt cap
- 19.13M
- Vol
- 504.33K
- Avg vol
- 752.38K
- EPS
- -0.07
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.1808
- High
- 0.197
- Forward P/E
- -3.74
- Beta
- 1.29
- Short ratio
- 2.29
- Inst. own
- 22.00%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 12, 2025
- 50-d avg
- 0.3768
- 200-d avg
- 0.421
- 1y target
- 3.75
YTD chart
Signals (56)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 29, 2026 | 4 days ago |
| RSI: Oversold | Oct 19, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 14, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 6, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| SMA: Bearish | Sep 24, 2026 | 1 month ago |
| SMA: Bullish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 22, 2026 | 1 month ago |
| SMA: Bearish | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Sep 21, 2026 | 1 month ago |
| SMA: Bullish | Sep 18, 2026 | 1 month ago |
| SMA: Bullish | Sep 18, 2026 | 1 month ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 3, 2026 | 2 months ago |
| RSI: Overbought | Aug 27, 2026 | 2 months ago |
| SMA: Bullish | Aug 21, 2026 | 2 months ago |
| SMA: Bearish | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 14, 2026 | 2 months ago |
| RSI: Overbought | Aug 14, 2026 | 2 months ago |
| SMA: Bullish | Aug 11, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| RSI: Oversold | Jul 29, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 27, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 21, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 16, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 2, 2026 | 4 months ago |
| RSI: Oversold | Jun 25, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 10, 2026 | 4 months ago |
| SMA: Bearish | Jun 4, 2026 | 5 months ago |
| SMA: Bullish | Jun 3, 2026 | 5 months ago |
| MACD: Buy Signal | Jun 3, 2026 | 5 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| SMA: Bullish | Jun 1, 2026 | 5 months ago |
| SMA: Bearish | May 15, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 29, 2026 | 6 months ago |
| SMA: Bearish | Apr 27, 2026 | 6 months ago |
| SMA: Bullish | Apr 22, 2026 | 6 months ago |
| RSI: Overbought | Apr 22, 2026 | 6 months ago |
| SMA: Bearish | Apr 20, 2026 | 6 months ago |
| SMA: Bullish | Apr 17, 2026 | 6 months ago |
| RSI: Overbought | Apr 15, 2026 | 6 months ago |
| SMA: Bullish | Apr 8, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 7, 2026 | 6 months ago |
| SMA: Bearish | Mar 24, 2026 | 7 months ago |
| SMA: Bullish | Mar 20, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 19, 2026 | 7 months ago |
| SMA: Bullish | Mar 3, 2026 | 8 months ago |
| SMA: Bearish | Feb 26, 2026 | 8 months ago |
| SMA: Bullish | Feb 25, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 17, 2026 | 8 months ago |
| RSI: Oversold | Feb 5, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 30, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 22, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 21, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 7, 2026 | 9 months ago |
Key statistics
- Market cap
- 28.94M
- Enterprise value
- 26.29M
- Trailing P/E
- 0.00
- Forward P/E
- -3.74
- PEG ratio
- 0.00
- Price / sales
- 27.25
- Price / book
- 3.40
- EPS (TTM)
- -0.20
- Beta
- 1.29
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.06M
- Revenue growth
- -51.00%
- Free cash flow
- -3.51M
- Total cash
- 1.82M
- Total debt
- 338.00K
- Return on equity
- -126.20%
- Shares outstanding
- 77.45M
- Short % of float
- 2.40%
- 50-day average
- 0.3768
- 200-day average
- 0.421
Analyst view
Consensus: none
Price target (mean) 3.75 +1927.0% upside
Now 0.185
- Target (low)
- 3.50
- Target (mean)
- 3.75
- Target (high)
- 4.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 12, 2025
Expected Feb 12, 2025. Consensus EPS estimate -0.03.
Financials — quick view
IGC Revenue — quarterly 265.00K
IGC Net income — quarterly -2.94M
IGC EPS — quarterly -0.03
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 12, 2025 | Dec 1, 2024 | -0.03 | — | — | — |
| Nov 12, 2024 | Sep 1, 2024 | -0.03 | -0.02 | +0.01 | +33.33% |
| Aug 8, 2024 | Jun 1, 2024 | 0.00 | -0.03 | — | — |
| Jun 24, 2024 | Mar 1, 2024 | 0.00 | -0.04 | — | — |
| Feb 14, 2024 | Dec 1, 2023 | 0.00 | -0.09 | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | -0.05 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2024 | Ascendiant Capital | main | Buy | Buy |
| Sep 3, 2024 | Ascendiant Capital | main | Buy | Buy |
| Jul 29, 2024 | Ascendiant Capital | main | Buy | Buy |
| Jul 17, 2024 | Alliance Global Partners | init | — | Buy |
| Jun 21, 2024 | Ascendiant Capital | reit | Buy | Buy |
About IGC Pharma, Inc.
IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- igcpharma.com
News
- Why Celestica Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- 'DEA Judge Pauses Marijuana Rescheduling Hearing As Opponents Highlight Government Report Detailing ‘Gaps’ In Federal Processes'- Marijuana Moment
- Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $6
- IGC Pharma Q2 EPS $(0.03) Misses $(0.02) Estimate, Sales $265.000K Beat $258.000K Estimate
- IGC Pharma Says CEO Ram Mukunda And Principal Financial Officer Claudia Grimaldi Purchase Aggregate Of 4,274,853 Shares Directly From Company At $0.27/Shr
- IGC Pharma Launches AI-Powered Data Harmonization Platform To Accelerate Alzheimer’s Research And Drug Discovery
- Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $5.5
- 'White House Pushes Congress To Keep Hemp CBD Products Legal By Amending Broad Ban That's Set To Take Effect Later This Year' - Marijuana Moment
- IGC Pharma Announces Addition Of Icahn School Of Medicine At Mount Sinai In New York As Clinical Site In Phase 2 CALMA Trial Evaluating IGC-AD1 For Agitation Associated With Alzheimer's Disease
Your note
Sign in to keep a note on IGC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRADBURY STRATEGIC INVESTMENT FUND A | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Mar 21, 2024 | 13,823,500 |
| GRIMALDI CLAUDIA | Director | Conversion of Exercise of derivative security | Mar 12, 2024 | 1,037,150 |
| MORAN JAMES P | Director | Purchase | Sep 24, 2024 | 0 |
| MUKUNDA RAM | Chief Executive Officer | Stock Gift | Mar 12, 2024 | 4,336,760 |
| PRINS RICHARD K | Director | Stock Gift | Aug 11, 2024 | 1,042,920 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 1.78% | 703,798 | 263.01K | Sep 29, 2024 |
| Vanguard Group Inc | 1.63% | 645,166 | 241.10K | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.42% | 562,969 | 210.38K | Sep 29, 2024 |
| State Street Corporation | 0.42% | 165,307 | 61.77K | Sep 29, 2024 |
| Virtu Financial LLC | 0.31% | 123,060 | 45.99K | Sep 29, 2024 |
| Dearborn Partners, L.L.C. | 0.29% | 116,401 | 43.50K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 1.59% | 630,222 | 235.51K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.98% | 387,255 | 144.72K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.25% | 99,144 | 37.05K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.23% | 91,469 | 34.18K | Oct 30, 2024 |